News
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: PAION AG announces change in Management Board
EQS-News: PAION AG announces change in Management Board
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology company working to extend survival
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company’s Vice Chair of the Board of
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease